Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
BRAF mutation
i
Other names:
BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
673
Related biomarkers:
Mutation
CNA
Fusion
Others
‹
›
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
BRAF mutation
Melanoma
BRAF mutation
Melanoma
dabrafenib + granisetron intravenous
Sensitive: A2 - Guideline
dabrafenib + granisetron intravenous
Sensitive
:
A2
dabrafenib + granisetron intravenous
Sensitive: A2 - Guideline
dabrafenib + granisetron intravenous
Sensitive
:
A2
BRAF mutation
Colorectal Cancer
BRAF mutation
Colorectal Cancer
ramucirumab
Sensitive: B - Late Trials
ramucirumab
Sensitive
:
B
ramucirumab
Sensitive: B - Late Trials
ramucirumab
Sensitive
:
B
BRAF mutation
Colorectal Cancer
BRAF mutation
Colorectal Cancer
ziv-aflibercept IV
Sensitive: B - Late Trials
ziv-aflibercept IV
Sensitive
:
B
ziv-aflibercept IV
Sensitive: B - Late Trials
ziv-aflibercept IV
Sensitive
:
B
BRAF mutation
Colorectal Cancer
BRAF mutation
Colorectal Cancer
bevacizumab
Sensitive: B - Late Trials
bevacizumab
Sensitive
:
B
bevacizumab
Sensitive: B - Late Trials
bevacizumab
Sensitive
:
B
BRAF mutation
Colorectal Cancer
BRAF mutation
Colorectal Cancer
cetuximab
Resistant: B - Late Trials
cetuximab
Resistant
:
B
cetuximab
Resistant: B - Late Trials
cetuximab
Resistant
:
B
BRAF mutation
Colorectal Cancer
BRAF mutation
Colorectal Cancer
regorafenib
Sensitive: B - Late Trials
regorafenib
Sensitive
:
B
regorafenib
Sensitive: B - Late Trials
regorafenib
Sensitive
:
B
BRAF mutation
Melanoma
BRAF mutation
Melanoma
nivolumab + ipilimumab
Sensitive: B - Late Trials
nivolumab + ipilimumab
Sensitive
:
B
nivolumab + ipilimumab
Sensitive: B - Late Trials
nivolumab + ipilimumab
Sensitive
:
B
BRAF mutation
Colorectal Cancer
BRAF mutation
Colorectal Cancer
FOLFIRI + cetuximab
Sensitive: B - Late Trials
FOLFIRI + cetuximab
Sensitive
:
B
FOLFIRI + cetuximab
Sensitive: B - Late Trials
FOLFIRI + cetuximab
Sensitive
:
B
BRAF mutation
Acute Myelogenous Leukemia
BRAF mutation
Acute Myelogenous Leukemia
gilteritinib
Resistant: B - Late Trials
gilteritinib
Resistant
:
B
gilteritinib
Resistant: B - Late Trials
gilteritinib
Resistant
:
B
BRAF mutation
Melanoma
BRAF mutation
Melanoma
PD-L1 inhibitor
Sensitive: B - Late Trials
PD-L1 inhibitor
Sensitive
:
B
PD-L1 inhibitor
Sensitive: B - Late Trials
PD-L1 inhibitor
Sensitive
:
B
BRAF mutation
Melanoma
BRAF mutation
Melanoma
ipilimumab
Sensitive: B - Late Trials
ipilimumab
Sensitive
:
B
ipilimumab
Sensitive: B - Late Trials
ipilimumab
Sensitive
:
B
BRAF mutation
Melanoma
BRAF mutation
Melanoma
KIN-2787
Sensitive: B - Late Trials
KIN-2787
Sensitive
:
B
KIN-2787
Sensitive: B - Late Trials
KIN-2787
Sensitive
:
B
BRAF mutation
Colorectal Cancer
BRAF mutation
Colorectal Cancer
panitumumab
Sensitive: C2 – Inclusion Criteria
panitumumab
Sensitive
:
C2
panitumumab
Sensitive: C2 – Inclusion Criteria
panitumumab
Sensitive
:
C2
BRAF mutation
Melanoma
BRAF mutation
Melanoma
encorafenib + binimetinib
Sensitive: C2 – Inclusion Criteria
encorafenib + binimetinib
Sensitive
:
C2
encorafenib + binimetinib
Sensitive: C2 – Inclusion Criteria
encorafenib + binimetinib
Sensitive
:
C2
BRAF mutation
Thyroid Gland Carcinoma
BRAF mutation
Thyroid Gland Carcinoma
selumetinib
Sensitive: C2 – Inclusion Criteria
selumetinib
Sensitive
:
C2
selumetinib
Sensitive: C2 – Inclusion Criteria
selumetinib
Sensitive
:
C2
BRAF mutation
Melanoma
BRAF mutation
Melanoma
BVD-523
Sensitive: C2 – Inclusion Criteria
BVD-523
Sensitive
:
C2
BVD-523
Sensitive: C2 – Inclusion Criteria
BVD-523
Sensitive
:
C2
BRAF mutation
Melanoma
BRAF mutation
Melanoma
trametinib
Sensitive: C2 – Inclusion Criteria
trametinib
Sensitive
:
C2
trametinib
Sensitive: C2 – Inclusion Criteria
trametinib
Sensitive
:
C2
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
atezolizumab + cobimetinib
Sensitive: C2 – Inclusion Criteria
atezolizumab + cobimetinib
Sensitive
:
C2
atezolizumab + cobimetinib
Sensitive: C2 – Inclusion Criteria
atezolizumab + cobimetinib
Sensitive
:
C2
BRAF mutation
Colon Cancer
BRAF mutation
Colon Cancer
bevacizumab
Sensitive: C2 – Inclusion Criteria
bevacizumab
Sensitive
:
C2
bevacizumab
Sensitive: C2 – Inclusion Criteria
bevacizumab
Sensitive
:
C2
BRAF mutation
Melanoma
BRAF mutation
Melanoma
selumetinib
Sensitive: C2 – Inclusion Criteria
selumetinib
Sensitive
:
C2
selumetinib
Sensitive: C2 – Inclusion Criteria
selumetinib
Sensitive
:
C2
BRAF mutation
Pancreatic Cancer
BRAF mutation
Pancreatic Cancer
vemurafenib
Sensitive: C2 – Inclusion Criteria
vemurafenib
Sensitive
:
C2
vemurafenib
Sensitive: C2 – Inclusion Criteria
vemurafenib
Sensitive
:
C2
BRAF mutation
Thyroid Gland Papillary Carcinoma
BRAF mutation
Thyroid Gland Papillary Carcinoma
vemurafenib
Sensitive: C2 – Inclusion Criteria
vemurafenib
Sensitive
:
C2
vemurafenib
Sensitive: C2 – Inclusion Criteria
vemurafenib
Sensitive
:
C2
BRAF mutation
Melanoma
BRAF mutation
Melanoma
nivolumab
Sensitive: C2 – Inclusion Criteria
nivolumab
Sensitive
:
C2
nivolumab
Sensitive: C2 – Inclusion Criteria
nivolumab
Sensitive
:
C2
BRAF mutation
Rectal Cancer
BRAF mutation
Rectal Cancer
bevacizumab
Sensitive: C2 – Inclusion Criteria
bevacizumab
Sensitive
:
C2
bevacizumab
Sensitive: C2 – Inclusion Criteria
bevacizumab
Sensitive
:
C2
BRAF mutation
Melanoma
BRAF mutation
Melanoma
pembrolizumab
Sensitive: C2 – Inclusion Criteria
pembrolizumab
Sensitive
:
C2
pembrolizumab
Sensitive: C2 – Inclusion Criteria
pembrolizumab
Sensitive
:
C2
BRAF mutation
Colorectal Cancer
BRAF mutation
Colorectal Cancer
nivolumab + bevacizumab
Sensitive: C2 – Inclusion Criteria
nivolumab + bevacizumab
Sensitive
:
C2
nivolumab + bevacizumab
Sensitive: C2 – Inclusion Criteria
nivolumab + bevacizumab
Sensitive
:
C2
BRAF mutation
Melanoma
BRAF mutation
Melanoma
vemurafenib + cobimetinib
Sensitive: C2 – Inclusion Criteria
vemurafenib + cobimetinib
Sensitive
:
C2
vemurafenib + cobimetinib
Sensitive: C2 – Inclusion Criteria
vemurafenib + cobimetinib
Sensitive
:
C2
BRAF mutation
Melanoma
BRAF mutation
Melanoma
cobimetinib
Sensitive: C2 – Inclusion Criteria
cobimetinib
Sensitive
:
C2
cobimetinib
Sensitive: C2 – Inclusion Criteria
cobimetinib
Sensitive
:
C2
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
vemurafenib
Sensitive: C2 – Inclusion Criteria
vemurafenib
Sensitive
:
C2
vemurafenib
Sensitive: C2 – Inclusion Criteria
vemurafenib
Sensitive
:
C2
BRAF mutation
Non Small Cell Lung Cancer
BRAF mutation
Non Small Cell Lung Cancer
PD-L1 inhibitor
Sensitive: C3 – Early Trials
PD-L1 inhibitor
Sensitive
:
C3
PD-L1 inhibitor
Sensitive: C3 – Early Trials
PD-L1 inhibitor
Sensitive
:
C3
BRAF mutation
Non Small Cell Lung Cancer
BRAF mutation
Non Small Cell Lung Cancer
PD1 inhibitor
Sensitive: C3 – Early Trials
PD1 inhibitor
Sensitive
:
C3
PD1 inhibitor
Sensitive: C3 – Early Trials
PD1 inhibitor
Sensitive
:
C3
BRAF mutation
Melanoma
BRAF mutation
Melanoma
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login